Compare Coursera Inc (COUR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs TG Therapeutics Inc — how do they compare? Coursera Inc trades at $5.65 (market cap $1.50B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 5.1× Coursera Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | TGTX | |
|---|---|---|
Market Cap | $1.50B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $59.06 |
52-Week Low | $5.09 | $26.94 |
Enterprise Value | $759.54M | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.575, down 3.21% today, with a bearish technical signal and mixed earnings performance. Revenue growth continues with 2025 reaching $757.5M, though the company remains unprofitable with a -15.39% net margin. Recent Q2 2026 earnings beat expectations at $0.17 per share versus $0.10 expected. Analyst sentiment is positive with 53% buy ratings and a $7.70 consensus price target representing 38% upside potential.
The stock offers growth exposure to online education but faces profitability challenges. Upside catalysts include continued revenue expansion and strategic AI investments, while risks include persistent losses and competitive pressures. Wall Street sees significant undervaluation despite near-term headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
